Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis.
Min Sung YoonHee Seung LeeChang Moo KangWoo Jung LeeJiyoung KeumMin Je SungSeung-Seob KimMi-Suk ParkJung Hyun JoMoon Jae ChungJeong Youp ParkSeung Woo ParkSi Young SongHo Kyoung HwangSeungmin BangPublished in: Gut and liver (2021)
We observed significantly better surgical outcomes and progression-free survival with the addition of neoadjuvant therapy to the management of resectable PDAC. However, despite PSM, there was still selection bias due to the use of different regimens between the groups receiving surgery first and neoadjuvant therapy. Large homogeneous samples are needed in the future prospective studies.